A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients-Reference-Cited by-同舟云学术

A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients

Published:2022-02-25 Issue:4 Volume:38 Page:565-570
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Fleishman Nathan R.¹,Richardson Troy²,Attard Thomas M.³^ORCID

Affiliation:

1. Department of Gastroenterology, Levine Children’s Hospital, Charlotte, North Carolina, USA

2. Children's Hospital Association, Lenexa, Kansas, USA

3. Department of Gastroenterology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2037847

Reference19 articles.

1. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW

2. Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals

3. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market | FDA. [cited 2020 Dec 22]. Accessed from: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.

4. Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 mg/mL, Due to Potential Levels of N-nitrosodimethylamine (NDMA) Impurity Amounts Above the Levels Established by FDA | FDA. [citeed 2021 April 13]. Accessed from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-nizatidine-oral-solution-15-mgml-due.